Beyond Aducanumab: Neurimmune Advances Portfolio Of Clinical Candidates

 
• By Mandy Jackson
  
Signpost outside is showing Phase 1 and Phase 2
Neurimmune is transitioning from a Phase I to a Phase II company • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business